Wet AMD treatment news from ARVO2016

Posted: Wednesday 04 May 2016

Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that data from a preclinical study of its lead product, GB-102, a novel injectable depot formulation containing a compound blocking VEGF and PDGF receptors for twice a year treatment of wet AMD, was presented in a poster session today at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, WA.

Raquel Formica, PhD, a senior investigator in the Retinal Cell and Molecular Laboratory directed by Peter A. Campochiaro, MD, at the Wilmer Eye Institute of Johns Hopkins University, in collaboration with Justin Hanes, PhD, the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, a renowned bioengineer with extensive expertise in polymer chemistry and drug delivery, presented data demonstrating prolonged suppression of choroidal neovascularization (CNV) after a single intravitreous injection of GB-102 in a poster entitled, "Sustained Suppression of Murine Choroidal Neovascularization by Intravitreous Injection of Sunitinib-encapsulated Polymer Microparticles."